Income before deduction of interest, taxes and amortization: neurosense-tx.com (NRSN)
NeuroSense Therapeutics (NRSN) was preparing for the final stage of clinical trials for its ALS drug. The absolute EBITDA trend currently reflects cash flow dynamics, where the 0.00 metric indicates the status of operational efficiency. Prospects are based on FDA approval and M&A deals, provided there is strict adherence to temperature controls during the transportation of biomaterials to laboratories.
Summary analytical data breakdowns for NeuroSense Therapeutics Ltd. (NRSN)
- market price and analyst price targets:
- company stock exchange capitalization indicators:
- book capitalization information:
- debt level and financial liquidity data:
Debt to Capital NeuroSense Therapeutics|NRSN - Long-Term Debt to Equity|Short-Term Debt to Capital Ratio NeuroSense Therapeutics Ltd|NRSN - Company Debts|Debts to Net Assets NeuroSense Therapeutics|NRSN - Company Long-Term Debts|Short-Term Debt NeuroSense Therapeutics|Intermediate Coverage Ratio neurosense-tx.com
- earnings and market multiples details:
NRSN - Net Income|Future Net Profit NeuroSense Therapeutics|NRSN - P/E Multiple|Future Price to Earnings Multiple NeuroSense Therapeutics Ltd|NRSN - PEG Multiple|Company Value to EBITDA NeuroSense Therapeutics|NRSN - Profit before payment of interest, taxes and amortization|Earnings per share for the trailing year NeuroSense Therapeutics|NRSN - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth neurosense-tx.com|NRSN - Earnings per share growth in current year|Net earnings per share change forecast for next year NeuroSense Therapeutics
Analysis of all company metrics:NRSN NeuroSense Therapeutics
This indicator measures real cash flow from operating activities, determining the business's ability to generate cash excluding debt load and depreciation. By analyzing absolute profit from core operations, an investor assesses the resilience of NeuroSense Therapeutics (NRSN) to market shocks, which is critical when diversifying the development of combination therapies for neurodegenerative diseases to minimize specific scientific risks.
Who NeuroSense Therapeutics competes with
Operating profit EBITDA Biogen Idec BIIB|NBIX - Profit before payment of interest, taxes and amortization|Income before deduction of interest, taxes and amortization RGC (regencellbioscience.com)|Axsome Therapeutics, Inc. (AXSM) - Profit before payment of interest, taxes and amortization|Profit before interest, taxes and amortization ACADIA Pharma (ACAD)|Profit before payment of interest, taxes and amortization Xenon Pharmaceuticals Inc|Viking Therapeutics Corp (VKTX) - Operating income before deduction of amortization|Operating profit EBITDA SUPN|CPRX - Profit before interest, taxes and amortization|Profit before payment of interest, taxes and amortization Denali Therapeutics Inc. DNLI|HRMY: Operating profit before amortization|BHVN - Profit before payment of interest, taxes and amortization|Operating income before deduction of amortization Amylyx Corp AMLX|TRVI: Operating profit EBITDA|Profit before interest, taxes and amortization praxismedicines.com (PRAX)|Operating profit before deduction of amortization AVXL|CBLL: Income before deduction of interest, taxes and amortization|Operating profit before deduction of amortization PRTA (Prothena Corp)|Company profit before taxes, interest and amortization ALEC|Operating profit EBITDA ANNX (Annexon, Inc.)|Income before deduction of interest, taxes and amortization OMER|Neurogene - Operating profit EBITDA|Profit before interest, taxes and amortization AC Immune S.A.|Voyager Pharma (VYGR) - Profit before payment of interest, taxes and amortization|Neumora Corp - Income before deduction of interest, taxes and amortization|SCLX (Scilex Holding Company) - Operating profit EBITDA|Operating profit EBITDA tevogen.com|Profit before payment of interest, taxes and amortization Alpha Cognition (ACOG)|CGTX: Profit before deduction of interest, taxes, depreciation and amortization|Operating profit EBITDA IKT (Inhibikase)|Cassava Pharma (SAVA) - Profit before interest, taxes and amortization|ASRT: Operating profit before deduction of amortization|COYA - Operating profit EBITDA|VTGN (vistagen.com) - Operating profit before deduction of amortization|OVID: Company profit before taxes, interest and amortization|ABOS (Acumen Pharma) - Operating profit EBITDA|CervoMed Corporation (CRVO) - Operating income before deduction of amortization|Operating profit EBITDA ATHE|Operating profit before deduction of amortization clene.com CLNN|Profit before payment of interest, taxes and amortization PepGen PEPG|Operating income before deduction of amortization Jupiter Neurosciences, Inc. (JUNS)|RLMD - Profit before payment of interest, taxes and amortization|ANVS (Annovis Bio Corporation) - Operating profit before amortization|gracetx.com (GRCE) - Profit before payment of interest, taxes and amortization|fireflyneuro.com - Income before deduction of interest, taxes and amortization|Profit before payment of interest, taxes and amortization ANEW Medical|Reviva Pharmaceuticals Holdings Inc. (RVPH) - Operating income before deduction of amortization|Profit before payment of interest, taxes and amortization MetaVia Inc (MTVA)|NeurAxis Inc - Operating profit before amortization|Profit before payment of interest, taxes and amortization Helius Medical Technologies HSDT|PASG: Operating profit before amortization|Neuphoria - Operating profit EBITDA|Profit before interest, taxes and amortization Minerva Neurosciences Inc|ATHA (Athira) - Operating profit before deduction of amortization|Addex (ADXN) - Operating profit EBITDA|Profit before payment of interest, taxes and amortization Alzamend Neuro Inc.|CYCN: Income before deduction of interest, taxes and amortization|Profit before payment of interest, taxes and amortization Protagenic Therapeutics (PTIX)|KTTA - Profit before interest, taxes and amortization|Profit before payment of interest, taxes and amortization Cortigent CRGT|ATXI: Operating profit before amortization|Brainstorm Cell - Operating profit EBITDA|Profit before interest, taxes and amortization caratherapeutics.com|CHRO (Chromocell Therapeutics Corp.) - Operating profit before deduction of amortization|Eliem Therapeutics Inc. (ELYM) - Operating profit EBITDA|Profit before payment of interest, taxes and amortization Intra-Cellular Therapies Inc.|LBPH: Income before deduction of interest, taxes and amortization|Profit before payment of interest, taxes and amortization Marinus Pharmaceuticals (MRNS)|NKGN - Profit before interest, taxes and amortization|Profit before payment of interest, taxes and amortization NeuroBo Pharmaceuticals, Inc. NRBO|Operating income before deduction of amortization Sage Therapeutics Inc. (SAGE)|Neurotrope - Operating profit EBITDA|Profit before interest, taxes and amortization Trevena Inc|vigilneuro.com (VIGL) - Profit before payment of interest, taxes and amortization|Operating profit before amortization WENA|Profit before payment of interest, taxes and amortization Cerevel Therapeutics, Inc.
